Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSMED IncINSM · Entity 3174 | Director · Chair and CEO | July 23, 2026 | July 24, 2026 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Director | January 07, 2026 | January 10, 2026 |
| uniQure N.V.QURE · Entity 4162 | Director | January 27, 2017 | January 31, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSMED Inc
Report date July 23, 2026 · Filed July 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 259,058 |
Ending reported balance
After 2026-07-23 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-07-23 · Exercise / conversion · Acquired 6,260 · Balance 265,318 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 2 · 2026-07-23 · Exercise / conversion · Acquired 4,440 · Balance 269,758 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 3 · 2026-07-23 · Sale · Disposed 4,828 · Balance 264,930 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Row 4 · 2026-07-23 · Sale · Disposed 5,872 · Balance 259,058 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.46 · Expires 2028-01-04 | Direct | 0 |
Reported balance
After 2026-07-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-23 · Exercise / conversion · Disposed 6,260 · Balance 0 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.16 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2026-07-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-23 · Exercise / conversion · Disposed 4,440 · Balance 0 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 233,924 |
Reported balance
Holding disclosure · report date 2026-07-23 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 233,924 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F3: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
NewAmsterdam Pharma Co N.V.
Report date January 07, 2026 · Filed January 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,360 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 3,400 · Balance 10,360 F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2: Each RSU was granted on January 7, 2026 for no consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.45 · Expires 2036-01-07 | Direct | 15,300 |
Reported balance
After 2026-01-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-07 · Grant · Acquired 15,300 · Balance 15,300 F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
F2: Each RSU was granted on January 7, 2026 for no consideration.
F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
uniQure N.V.
Report date January 27, 2017 · Filed January 31, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.37 · Expires 2027-01-27 | Direct | 11,000 |
Reported balance
After 2017-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-27 · Grant · Acquired 11,000 · Balance 11,000 F1: The Stock Option vests 100% on January 27, 2018. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 16,000 |
Reported balance
After 2017-01-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-27 · Grant · Acquired 11,000 · Balance 16,000 F2: The Restricted Stock Unit vests 100% on January 27, 2018. F3: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option vests 100% on January 27, 2018.
F2: The Restricted Stock Unit vests 100% on January 27, 2018.
F3: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2025 Filed Apr 3, 2025 20:25 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,021 | $72.29 | $218,388.09 |
DisclosureSEC source: 0001628280-25-016508 · wk-form4_1743711913.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 237,733 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 3,021 shares sold at prices ranging from $72.00 to $72.88 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:25 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001628280-25-016508 · wk-form4_1743711913.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:53 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-25-013864 · wk-form4_1742417573.xml · derivative · entry 11 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 191,310 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:53 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.76 | $0.00 |
DisclosureSEC source: 0001628280-25-013864 · wk-form4_1742417573.xml · derivative · entry 10 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,750 shares Expires 2025-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:53 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,737 | $77.83 | $213,020.71 |
DisclosureSEC source: 0001628280-25-013864 · wk-form4_1742417573.xml · nonDerivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: This is the weighted average sales price representing 2,737 shares sold at prices ranging from $77.72 to $77.99 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:53 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,070 | $77.01 | $159,410.70 |
DisclosureSEC source: 0001628280-25-013864 · wk-form4_1742417573.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 236,661 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 2,070 shares sold at prices ranging from $76.54 to $77.50 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:53 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,023 | $76.00 | $153,748.00 |
DisclosureSEC source: 0001628280-25-013864 · wk-form4_1742417573.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 238,731 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 2,023 shares sold at prices ranging from $75.52 to $76.47 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:53 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001628280-25-013864 · wk-form4_1742417573.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:53 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 8,116 | $77.79 | $631,343.64 |
DisclosureSEC source: 0001628280-25-013864 · wk-form4_1742417573.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 334,186 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 8,116 shares sold at prices ranging from $77.34 to $78.06 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:53 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 5,907 | $76.87 | $454,071.09 |
DisclosureSEC source: 0001628280-25-013864 · wk-form4_1742417573.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 342,302 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 5,907 shares sold at prices ranging from $76.32 to $77.31 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:53 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 4,727 | $75.91 | $358,826.57 |
DisclosureSEC source: 0001628280-25-013864 · wk-form4_1742417573.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 348,209 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 4,727 shares sold at prices ranging from $75.32 to $76.31 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:53 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 18,750 | $22.76 | $426,750.00 |
DisclosureSEC source: 0001628280-25-013864 · wk-form4_1742417573.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 352,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:27 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-25-010590 · wk-form4_1741213663.xml · derivative · entry 15 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 198,140 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F10 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:27 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.76 | $0.00 |
DisclosureSEC source: 0001628280-25-010590 · wk-form4_1741213663.xml · derivative · entry 14 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2025-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F10 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:27 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 46 | $80.90 | $3,721.40 |
DisclosureSEC source: 0001628280-25-010590 · wk-form4_1741213663.xml · nonDerivative · entry 12 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:27 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 377 | $79.73 | $30,058.21 |
DisclosureSEC source: 0001628280-25-010590 · wk-form4_1741213663.xml · nonDerivative · entry 11 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,970 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F9 · price: This is the weighted average sales price representing 377 shares sold at prices ranging from $79.53 to $79.90 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:27 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,250 | $78.97 | $177,682.50 |
DisclosureSEC source: 0001628280-25-010590 · wk-form4_1741213663.xml · nonDerivative · entry 10 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 234,347 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · price: This is the weighted average sales price representing 2,250 shares sold at prices ranging from $78.49 to $79.42 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:27 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,486 | $78.20 | $116,205.20 |
DisclosureSEC source: 0001628280-25-010590 · wk-form4_1741213663.xml · nonDerivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 236,597 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: This is the weighted average sales price representing 1,486 shares sold at prices ranging from $77.48 to $78.46 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:27 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,671 | $76.23 | $203,610.33 |
DisclosureSEC source: 0001628280-25-010590 · wk-form4_1741213663.xml · nonDerivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 238,083 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 2,671 shares sold at prices ranging from $75.93 to $76.77 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:27 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001628280-25-010590 · wk-form4_1741213663.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:27 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 127 | $80.90 | $10,274.30 |
DisclosureSEC source: 0001628280-25-010590 · wk-form4_1741213663.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 334,186 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:27 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,785 | $79.43 | $221,212.55 |
DisclosureSEC source: 0001628280-25-010590 · wk-form4_1741213663.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 334,313 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 2,785 shares sold at prices ranging from $79.14 to $79.91 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:27 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 7,763 | $78.61 | $610,249.43 |
DisclosureSEC source: 0001628280-25-010590 · wk-form4_1741213663.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 337,098 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 7,763 shares sold at prices ranging from $78.13 to $79.11 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:27 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 758 | $77.75 | $58,934.50 |
DisclosureSEC source: 0001628280-25-010590 · wk-form4_1741213663.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 344,861 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 758 shares sold at prices ranging from $77.13 to $78.12 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:27 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 7,317 | $76.24 | $557,848.08 |
DisclosureSEC source: 0001628280-25-010590 · wk-form4_1741213663.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 345,619 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 7,317 shares sold at prices ranging from $75.91 to $76.90 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:27 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 18,750 | $22.76 | $426,750.00 |
DisclosureSEC source: 0001628280-25-010590 · wk-form4_1741213663.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 352,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:52 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-25-006807 · wk-form4_1740088354.xml · derivative · entry 11 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 204,970 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F9 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:52 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.76 | $0.00 |
DisclosureSEC source: 0001628280-25-006807 · wk-form4_1740088354.xml · derivative · entry 10 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 18,750 shares Expires 2025-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F9 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:52 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 300 | $81.81 | $24,543.00 |
DisclosureSEC source: 0001628280-25-006807 · wk-form4_1740088354.xml · nonDerivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · price: This is the weighted average sales price representing 300 shares sold at prices ranging from $81.69 to $82.01 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:52 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 6,074 | $81.07 | $492,419.18 |
DisclosureSEC source: 0001628280-25-006807 · wk-form4_1740088354.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 234,224 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: This is the weighted average sales price representing 6,074 shares sold at prices ranging from $80.51 to $81.42 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:52 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 456 | $80.00 | $36,480.00 |
DisclosureSEC source: 0001628280-25-006807 · wk-form4_1740088354.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,298 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 456 shares sold at prices ranging from $79.50 to $80.34 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:52 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001628280-25-006807 · wk-form4_1740088354.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:52 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 754 | $81.67 | $61,579.18 |
DisclosureSEC source: 0001628280-25-006807 · wk-form4_1740088354.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 334,186 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 754 shares sold at prices ranging from $81.56 to $81.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:52 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 16,743 | $81.08 | $1,357,522.44 |
DisclosureSEC source: 0001628280-25-006807 · wk-form4_1740088354.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 334,940 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 16,743 shares sold at prices ranging from $80.50 to $81.43 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:52 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,253 | $79.95 | $100,177.35 |
DisclosureSEC source: 0001628280-25-006807 · wk-form4_1740088354.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 351,683 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 1,253 shares sold at prices ranging from $79.50 to $80.35 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:52 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 18,750 | $22.76 | $426,750.00 |
DisclosureSEC source: 0001628280-25-006807 · wk-form4_1740088354.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 352,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Since the date of the last ownership report for the Reporting Person, he transferred 92,155 shares of Company common stock, employee stock options to purchase 1,064,717 shares of Company common stock, and restricted stock units covering 27,553 shares of Company common stock to his ex-spouse pursuant to a mutually agreed divorce settlement approved by a court that qualifies as a domestic relations order. A domestic relations order is a court order that dictates how assets should be divided between spouses during a divorce, including securities in the Company. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 22:11 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 79,350 | $80.90 | $6,419,415.00 |
DisclosureSEC source: 0001628280-25-004461 · wk-form4_1738966272.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 453,894 F2 · shares: Shares sold to satisfy tax withholding obligations upon the vesting of PSUs and to cover related broker fees. F3 · price: This is the weighted average sales price representing 79,350 shares sold at prices ranging from $80.57 to $81.43 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 22:11 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 153,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-004461 · wk-form4_1738966272.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533,244 F1 · shares: Represents shares of common stock acquired upon vesting of Performance Stock Units (PSUs) that were originally granted on January 6, 2022, which vested on February 5, 2025 upon the achievement of the applicable performance and service conditions. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:44 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · derivative · entry 13 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 211,800 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F9 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:44 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.76 | $0.00 |
DisclosureSEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · derivative · entry 12 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 18,750 shares Expires 2025-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F9 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:44 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,581 | $78.40 | $202,350.40 |
DisclosureSEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 10 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · price: This is the weighted average sales price representing 2,581 shares sold at prices ranging from $78.26 to $78.75 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:44 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,463 | $77.95 | $269,940.85 |
DisclosureSEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 236,505 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: This is the weighted average sales price representing 3,463 shares sold at prices ranging from $77.24 to $78.23 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:44 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 745 | $76.43 | $56,940.35 |
DisclosureSEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 239,968 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 745 shares sold at prices ranging from $76.10 to $76.90 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:44 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 41 | $74.86 | $3,069.26 |
DisclosureSEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,713 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:44 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:44 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 6,768 | $78.44 | $530,881.92 |
DisclosureSEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 379,534 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 6,768 shares sold at prices ranging from $78.31 to $78.80 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:44 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 9,869 | $77.97 | $769,485.93 |
DisclosureSEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 386,302 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 9,869 shares sold at prices ranging from $77.29 to $78.28 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:44 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,872 | $76.35 | $142,927.20 |
DisclosureSEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 396,171 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 1,872 shares sold at prices ranging from $76.00 to $76.57 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:44 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 241 | $75.25 | $18,135.25 |
DisclosureSEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 398,043 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 241 shares sold at prices ranging from $74.86 to $75.83 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:44 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 18,750 | $22.76 | $426,750.00 |
DisclosureSEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 398,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.